Automate Your Wheel Strategy on ARDX
With Tiblio's Option Bot, you can configure your own wheel strategy including ARDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ARDX
- Rev/Share 1.6462
- Book/Share 0.6378
- PB 12.1675
- Debt/Equity 1.3457
- CurrentRatio 4.4129
- ROIC -0.0939
- MktCap 1885478240.0
- FreeCF/Share -0.2288
- PFCF -34.0659
- PE -33.1973
- Debt/Assets 0.427
- DivYield 0
- ROE -0.3691
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | ARDX | Piper Sandler | Neutral | Overweight | -- | -- | Jan. 9, 2026 |
| Resumed | ARDX | Raymond James | -- | Strong Buy | -- | $14 | Sept. 3, 2025 |
| Resumed | ARDX | H.C. Wainwright | -- | Buy | -- | $10 | June 18, 2025 |
| Downgrade | ARDX | Raymond James | Strong Buy | Outperform | -- | $11 | May 2, 2025 |
| Resumed | ARDX | Ladenburg Thalmann | -- | Buy | -- | -- | March 7, 2025 |
| Initiation | ARDX | BTIG Research | -- | Buy | -- | $14 | March 4, 2025 |
News
Ardelyx: Assessment Of Acquisition Rumors
Published: January 21, 2026 by: Seeking Alpha
Sentiment: Neutral
Ardelyx: Assessment Of Acquisition Rumors
Read More
Are Medical Stocks Lagging Ardelyx (ARDX) This Year?
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Negative
Here is how Ardelyx (ARDX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Read More
Wall Street Analysts See a 92.12% Upside in Ardelyx (ARDX): Can the Stock Really Move This High?
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 92.1% in Ardelyx (ARDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Ardelyx (ARDX) Moves 5.5% Higher: Will This Strength Last?
Published: January 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Ardelyx (ARDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Read More
Ardelyx: A Long Overdue Rally
Published: November 04, 2025 by: Seeking Alpha
Sentiment: Positive
Ardelyx shares surged on Friday after strong Q3 results and positive guidance, validating patience during previous setbacks. The company demonstrated resilience, with recent financial performance supporting what should be renewed investor confidence in ARDX. Updated analysis highlights Ardelyx's improving fundamentals and potential for further upside following the latest quarterly report.
Read More
Ardelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Ardelyx, Inc. (NASDAQ:ARDX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Michael Raab - President, CEO & Director Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial & Operations Officer Conference Call Participants Robert Klingenberger Presentation Robert Klingenberger All right. Great. Good morning.
Read More
Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Negative
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Monday, August 4, 2025, at 4:30 p.m.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: June 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: June 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ardelyx, Inc. - ARDX
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President and CEO, will participate in a fireside chat at the Jefferies Global Healthcare Conference 2025 on Wednesday, June 4, 2025 at 8:10 am ET in New York.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
An Investigation Has Commenced on Behalf of Ardelyx, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your ARDX Losses
Published: May 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violations of federal securities laws. Ardelyx issued a press release on May 1, 2025, reporting its financial results for the first quarter of 2025.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: May 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Investors who Lost Money on Ardelyx, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - ARDX
Published: May 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violations of federal securities laws. Ardelyx issued a press release on May 1, 2025, reporting its financial results for the first quarter of 2025.
Read More
Ardelyx, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Ardelyx, Inc. (ARDX)
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violations of federal securities laws. Ardelyx issued a press release on May 1, 2025, reporting its financial results for the first quarter of 2025.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ardelyx, Inc. - ARDX
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Ardelyx, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - ARDX
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violations of federal securities laws. Ardelyx issued a press release on May 1, 2025, reporting its financial results for the first quarter of 2025.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Analysis of IBS in America 2024 Real-World Survey Demonstrates that severity of IBS-C correlates with financial hardship and distress Analysis of IBS in America 2024 Real-World Survey Demonstrates that severity of IBS-C correlates with financial hardship and distress
Read More
Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty
Published: May 02, 2025 by: Seeking Alpha
Sentiment: Negative
Ardelyx's Q1 earnings reveal a sequential drop in revenue and a sharp rise in SG&A expenses, leading to a substantial operational loss. The company faces reimbursement challenges for XPHOZAH, raising concerns about its future profitability and market position. Despite having solid liquidity, Ardelyx's high cash burn rate and debt pose sustainability risks, making its current valuation seem inflated.
Read More
Tenapanor Approved in China for Hyperphosphatemia
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval
Read More
Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade)
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Negative
Ardelyx, Inc. faces significant challenges in 2025 due to Xphozah's reimbursement issues and modest growth from Ibsrela, prompting a downgrade to "sell" and "market underperform." Xphozah's inclusion in a bundled system and loss of Medicare Part D coverage limits revenue potential, despite the company's $750 million annual sales guidance. Increased SG&A expenses and looming debt obligations raise concerns about Ardelyx's ability to achieve consistent profitability and fund necessary R&D investments.
Read More
About Ardelyx, Inc. (ARDX)
- IPO Date 2014-06-19
- Website https://www.ardelyx.com
- Industry Biotechnology
- CEO Michael G. Raab
- Employees 395